title: Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
abstract: Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.
authors.affiliation: Public Health, Epidemiology and Health Economics Department, University of Liège, Belgium, Liège, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Neuprez
authors.forename: S
authors.initials: S
authors.lastname: Coste
authors.forename: E
authors.initials: E
authors.lastname: Rompen
authors.forename: J M
authors.initials: JM
authors.lastname: Crielaard
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069448:Denosumab; D006801:Humans; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000209:etiology; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000209:etiology; D010024:Osteoporosis / Q000188:drug therapy*; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D014057:Tomography, X-Ray Computed; D014081:Tooth Extraction / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab